MA25562A1 - Procede pour administrer un inhibiteur de phosphodiesterase 4. - Google Patents

Procede pour administrer un inhibiteur de phosphodiesterase 4.

Info

Publication number
MA25562A1
MA25562A1 MA26618A MA26618A MA25562A1 MA 25562 A1 MA25562 A1 MA 25562A1 MA 26618 A MA26618 A MA 26618A MA 26618 A MA26618 A MA 26618A MA 25562 A1 MA25562 A1 MA 25562A1
Authority
MA
Morocco
Prior art keywords
phosphodiesterase
administering
inhibitor
Prior art date
Application number
MA26618A
Other languages
English (en)
Inventor
J Torphy Theodore
D Zussman Barry
D Murdoch Robert
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of MA25562A1 publication Critical patent/MA25562A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
MA26618A 1999-10-29 2002-04-26 Procede pour administrer un inhibiteur de phosphodiesterase 4. MA25562A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02

Publications (1)

Publication Number Publication Date
MA25562A1 true MA25562A1 (fr) 2002-10-01

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26618A MA25562A1 (fr) 1999-10-29 2002-04-26 Procede pour administrer un inhibiteur de phosphodiesterase 4.

Country Status (29)

Country Link
US (1) US20030212112A1 (fr)
EP (1) EP1225884A4 (fr)
JP (1) JP2003513038A (fr)
KR (1) KR20020050249A (fr)
CN (1) CN1387433A (fr)
AP (1) AP2002002446A0 (fr)
AR (1) AR026254A1 (fr)
AU (1) AU772909B2 (fr)
BG (1) BG106623A (fr)
BR (1) BR0015039A (fr)
CA (1) CA2389293A1 (fr)
CO (1) CO5271676A1 (fr)
CZ (1) CZ20021443A3 (fr)
DZ (1) DZ3249A1 (fr)
EA (1) EA200200502A1 (fr)
HK (1) HK1049105A1 (fr)
HU (1) HUP0203682A3 (fr)
IL (1) IL148813A0 (fr)
MA (1) MA25562A1 (fr)
MX (1) MXPA02004220A (fr)
NO (1) NO20021937L (fr)
NZ (1) NZ518002A (fr)
OA (1) OA12078A (fr)
PE (1) PE20011004A1 (fr)
PL (1) PL355262A1 (fr)
SK (1) SK7292002A3 (fr)
TR (1) TR200201150T2 (fr)
UY (1) UY26422A1 (fr)
WO (1) WO2001032165A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20060084684A1 (en) * 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
SI1606261T1 (sl) 2003-03-10 2010-03-31 Nycomed Gmbh Novi postopek za pripravo roflumilasta
EP1634606A1 (fr) * 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Medicament administre par voie orale
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
EP2506711B1 (fr) * 2009-12-03 2019-04-03 OPKO Health, Inc. Formulations de disaccharides hypersulfatés
BR112014015923B1 (pt) * 2011-12-27 2022-02-01 Amgen (Europe) GmbH Comprimidos revestidos de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metano-sulfoniletil]-4 - acetilaminoisoindolina-1,3-diona
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
WO2019147824A1 (fr) 2018-01-26 2019-08-01 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de pde4
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
WO2001032165A1 (fr) 2001-05-10
BG106623A (bg) 2003-02-28
PL355262A1 (en) 2004-04-05
OA12078A (en) 2003-05-28
AR026254A1 (es) 2003-02-05
SK7292002A3 (en) 2002-12-03
PE20011004A1 (es) 2001-09-28
EP1225884A1 (fr) 2002-07-31
TR200201150T2 (tr) 2002-09-23
BR0015039A (pt) 2002-06-25
NO20021937D0 (no) 2002-04-24
JP2003513038A (ja) 2003-04-08
KR20020050249A (ko) 2002-06-26
HUP0203682A2 (hu) 2003-04-28
NO20021937L (no) 2002-05-30
IL148813A0 (en) 2002-09-12
HK1049105A1 (zh) 2003-05-02
EA200200502A1 (ru) 2002-10-31
AP2002002446A0 (en) 2002-03-31
AU1344501A (en) 2001-05-14
HUP0203682A3 (en) 2003-10-28
DZ3249A1 (fr) 2001-05-10
MXPA02004220A (es) 2002-10-17
CN1387433A (zh) 2002-12-25
CA2389293A1 (fr) 2001-05-10
CZ20021443A3 (cs) 2003-01-15
NZ518002A (en) 2004-01-30
AU772909B2 (en) 2004-05-13
US20030212112A1 (en) 2003-11-13
CO5271676A1 (es) 2003-04-30
EP1225884A4 (fr) 2005-06-15
UY26422A1 (es) 2001-07-31

Similar Documents

Publication Publication Date Title
EP1113748A4 (fr) Procede pour former un extenseur biologique
EP0685658A3 (fr) Dispositif de retenue pour un écrou.
ZA200006577B (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors.
MA26250A1 (fr) PROCEDE DE CONTRôLE D'UN DETECTEUR.
ZA977694B (en) Heterocyclic metalloprotease inhibitors.
ZA200006116B (en) Distillation process for easily polymerizable substance-containing solution.
ID28489A (id) Metode untuk membuat 4-karboksiamino-2-disubstitusi 1,2,3,4-tetrahidroquinolin
MA25562A1 (fr) Procede pour administrer un inhibiteur de phosphodiesterase 4.
ZA200001333B (en) Method for communicating information.
ZA985416B (en) Apo B-secretion/MTP inhibitor hydrochloride salt.
ZA200105294B (en) Method for producing L-phenylephrine hydrochloride.
HUP0000536A2 (en) Method for levelling a track
ITGE20000114A0 (it) Dispositivo per l'agugliatura di un'ovatta.
FR2809260B1 (fr) Procede d'approvisionnement d'un compte prepaye
IT236376Y1 (it) Dispositivo di scarico per un crogiolo.
ZA200110053B (en) Factor via inhibitors.
EP1237112A4 (fr) Procede de realisation de transactions securisees sur livret bancaire electronique (tirelire)
ITRM990744A0 (it) Metodo per l'istallazione di elevatori.
ZA200108980B (en) Cold distillation method. Cold distillation method.
IT1317270B1 (it) Apparecchiatura a cambio di velocita' per un trattore.
FR2720409B1 (fr) Méthode pour détecter des composés antimicrobiens.
IT1316262B1 (it) Procedimento per il funzionamento di un autoveicolo.
IL141031A0 (en) New pharmaceutical uses for nos inhibitors
FR2833389B1 (fr) Systeme et procede visant a empecher le detournement d'avions.
ITBO980076A0 (it) Metodo per il trasferimento di articoli.